BackDyne Therapeutics Overview
Dyne Therapeutics Inc

Dyne Therapeutics Target Price

Analysts' 12-month price predictions for DYN.

Get informed when a big investor buys or sells

+ Follow

Share Price

$18.73

Average Target Price

$35.5089.5% upside

4 analysts in the last 4 months

High: $47 | Low: $24

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-05-15Evercore ISI$3376.2% upsideOpen
2026-05-13Bernstein$2428.1% upsideOpen
2026-03-02Chardan CapitalKeay Nakae$38102.9% upsideOpen
2026-03-02Morgan StanleyMichael E Ulz$47150.9% upsideOpen
2025-12-15Evercore ISIGavin Clark-Gartner$3692.2% upsideOpen
2025-12-11Stifel Nicolaus$39108.2% upsideOpen
2025-12-10Oppenheimer$40113.6% upsideOpen
2025-12-09Tudor PickeringWilliam Pickering$2322.8% upsideOpen
2025-12-09Bernstein$2322.8% upsideOpen
2025-12-08Morgan StanleyMichael E Ulz$50167% upsideOpen
2025-12-08Robert W. BairdBrian Skorney$3060.2% upsideOpen
2025-12-08H.C. WainwrightAndrew Fein$60220.3% upsideOpen
2025-12-08Raymond JamesMichael Freeman$40113.6% upsideOpen
2025-11-25Bernstein$2112.1% upsideOpen
2025-11-06Evercore ISIGavin Clark-Gartner$38102.9% upsideOpen
2025-10-10Oppenheimer$1330.6% downsideOpen
2025-08-25Raymond JamesStrong Buy$3586.9% upsideOpen
2025-06-02OppenheimerAndreas Argyrides$3481.5% upsideOpen
2025-02-28UBS$48156.3% upsideOpen
2025-02-28H.C. Wainwright$46145.6% upsideOpen
2024-08-14Morgan StanleyMichael Ulz$52177.6% upsideOpen
2024-08-13Piper SandlerEdward Tenthoff$53183% upsideOpen
2024-06-24JefferiesEun Yang$42124.2% upsideOpen
2024-06-17OppenheimerFrancois Brisebois$55193.6% upsideOpen
2024-05-21Chardan CapitalKeay Nakae$42124.2% upsideOpen
2024-05-20H.C. WainwrightAndrew Fein$48156.3% upsideOpen
2024-05-20Stifel NicolausPaul Matteis$41118.9% upsideOpen
2024-04-30Morgan StanleyMichael Ulz$40113.6% upsideOpen
2022-11-29J.P. Morgan$183.9% downsideOpen
2022-09-06Piper SandlerEdward Tenthoff$2322.8% upsideOpen
2022-07-12Piper SandlerEdward Tenthoff$179.2% downsideOpen